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Background: Recent genome-wide association studies have identified multiple loci that are associated with an
increased risk of developing coronary artery disease (CAD). The impact of these loci on the disease severity and
prognosis of ischemic heart failure due to CAD is currently unknown.
Methods: We undertook association analysis of 7 single nucleotide polymorphism (rs599839, rs17465637,
rs2972147, rs6922269, rs1333049, rs501120, and rs17228212) at 7 well established CAD risk loci (1p13.3, 1q41, 2q36.3,
6q25.1, 9p21.3, 10q11.21, and 15q22.33, respectively) in 3,320 subjects diagnosed with systolic heart failure of
ischemic aetiology and participating in the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA)
trial. The primary outcome was the composite of time to first event of cardiovascular death, non-fatal myocardial
infarction and non-fatal stroke, secondary outcomes included mortality and hospitalization due to worsening
heart failure.
Results: None of the 7 loci were significantly associated with the primary composite endpoint of the CORONA trial
(death from cardiovascular cases, nonfatal myocardial infarction, and nonfatal stroke). However, the 1p13.3 locus
(rs599839) showed evidence for association with all-cause mortality (after adjustment for covariates; HR 0.74, 95%CI
[0.61 to 0.90]; P = 0.0025) and we confirmed the 1p13.3 locus (rs599839) to be associated with lipid parameters (total
cholesterol (P = 1.1x10−4), low-density lipoprotein levels (P = 3.5 × 10−7) and apolipoprotein B (P = 2.2 × 10−10)).
Conclusion: Genetic variants strongly associated with CAD risk are not associated with the severity and outcome of
ischemic heart failure. The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in
further studies.
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Heart Failure (HF) is a highly prevalent condition affect-
ing more than 15 million patients in Europe alone and
has a poor prognosis [1]. In several familial forms of HF,
disease-causing mutations have been identified including
several mutations in genes coding for structural compo-
nents of the sarcomere [2,3]. For example, mutations in
the genes encoding cardiac β-myosin heavy chain
(MYH7) or cardiac myosin-binding protein C (MYBPC3)
are known to cause hypertrophic and dilated cardiomy-
opathies [4]. However, these Mendelian diseases only ac-
count for a small minority of all HF cases and only
explain a minor proportion of the population attribut-
able risk for HF. The vast majority of HF is a conse-
quence of more complex genetic and environmental
factors and the interactions among them. Coronary ar-
tery disease (CAD) is considered the major cause of HF.
For the development of CAD, a number of genetic risk
loci with common variants have recently been identified
[5-7]. The earliest findings derived from genome wide as-
sociation studies were reported by the Wellcome Trust
Case Control Consortium (WTCCC) and the German MI
Family GWA studies, as well as the Coronary Artery Dis-
ease consortium, which together have identified 7 common
variants that were robustly associated with CAD [5,7].
Whether these variants, with strong prior evidence to be
associated with increased CAD risk, are also relevant for
ischemic HF progression as reflected by HF severity and
prognosis remains to be determined. In the present study,
we have evaluated these 7 CAD risk loci in ischemic HF
patients participating in the COntrolled ROsuvastatin
multiNAtional study in heart failure (CORONA) and
tested the hypothesis that the SNPs associated with CAD
are also associated with ischemic HF disease severity and
outcome.
Methods
The current study is a genetic sub-study of the CORONA
trial. The CORONA trial aimed to determine the effect of
rosuvastatin treatment on clinical outcome in patients
with systolic heart failure from ischemic aetiology. The
CORONA study group is represented in the supplement.
The CORONA trial has been published in detail, the main
result was that rosuvastatin did not reduce the primary
composite outcome of death from cardiovascular causes,
nonfatal myocardial infarction, or nonfatal stroke [8,9].
Study population
In- and exclusion criteria of the CORONA trial have
been reported in detail previously [8,9]. In brief, patients
were 60 years of age or older, HF of ischemic aetiology,
and a left ventricular ejection fraction (LVEF) of ≤ 40%
with NYHA class III/IV symptoms or LVEF ≤ 35% with
NYHA class II symptoms. Patients had to be clinicallystable and on optimal treatment for at least 2 weeks be-
fore inclusion. Exclusion criteria included the following;
recent myocardial infarction (MI) (<6 months); unstable
angina or stroke within the past 3 months; percutaneous
coronary intervention (PCI) or coronary-artery bypass
grafting (CABG); the implantation of a cardioverter defib-
rillator (ICD) or biventricular pacemaker within the past
3 months; heart transplantation; clinically significant/un-
corrected primary valvular heart disease; hypertrophic car-
diomyopathy; or systemic disease (e.g., amyloidosis). The
CORONA trial included 5,011 patients [9], and DNA was
obtained from 3,340 of them. We excluded 20 non-
Caucasian subjects (8 black, 7 Asian, 5 ‘other’), leaving
3,320 subjects for the current genetic sub-study of COR-
ONA. The ethical committee at each of the participating
hospitals approved this trial (see Additional file 1), and
patients provided written informed consent.
Definition of phenotypes and outcome
The severity of HF was assessed by LVEF and serum N-
terminal pro B-type Natriuretic Peptide (NT-proBNP)
levels. As one of the loci has also been identified in a
GWAS for lipid traits, we specifically studied the associ-
ation of this locus with available lipid traits. The primary
outcome of the CORONA trial was the composite of death
from cardiovascular cases, nonfatal myocardial infarction,
and nonfatal stroke, analysed according to the time to the
first event. Secondary outcomes were death from any
cause, any coronary event (defined as sudden death, fatal or
nonfatal myocardial infarction, the performance of PCI or
CABG, ventricular defibrillation by an ICD, resuscitation
after cardiac arrest, or hospitalization for unstable angina),
death from cardiovascular causes, sudden death, death
from worsening heart failure, combination of mortality or
worsening heart failure and athero-thrombotic endpoint.
SNP selection and genotyping
We studied 7 loci (1p13.3, 1q41, 2q36.3, 6q25.1, 9p21.3,
10q11.21, 15q22.33) which have been linked to CAD risk
by previous GWAS [5,7]. We genotyped the 7 lead SNPs
within these loci; rs599839, rs17465637, rs2972147, rs69
22269, rs1333049, rs501120, and rs17228212 (Additional
file 2: Table S1). Genotyping was carried out with Taq-
Man (Applied Biosystems) using standard protocols and
was performed at the laboratory of AstraZeneca Phar-
maceuticals (JCF), Alderley Park, UK without knowledge
of clinical data.
Statistical analysis
Normality of the data was determined by visual inspec-
tion. HsCRP and NT-proBNP were non-normally dis-
tributed and therefore log-transformed. Genotypes were
coded additively as 0, 1 or 2 in terms of the number of
minor alleles. The baseline variables were analysed in linear
Table 1 Baseline characteristics of subjects in genetic
sub-study of CORONA
Characteristics of patients n = 3,320
Age (years) 72.3 ± 6.9
Males n (%) 2530 (76.2)
Left ventricular ejection fraction (% ± SD) 31 ± 6.3
NYHA class n (%)
II 1251 (37.7)
III 2035 (61.3)
IV 34 (1.0)
History of n (%)
Angina Pectoris 2463 (74.2)
Aortic Aneurysm 84 (2.5)
Aortic Aneurysm Surgery Performed 47 (1.4)
Atrial Fibrillation/Flutter 1318 (39.7)
Diabetes Mellitus 933 (28.1)
Hypertension 2173 (65.5)
Implantable cardioverter-defibrillator 79 (2.4)
Implanted pacemaker 349 (10.5)
Intermitted claudication 392 (11.8)
Myocardial infarction 1986 (59.8)
Coronary Artery Bypass Surgery 537 (16.2)
Percutaneous Coronary Intervention 358 (10.8)
CABG or PCI 823 (24.8)
Stroke 386 (11.6)
Smoking status n (%)
Non Smoker 1521 (45.8)
(Ex-)smoker 1797 (54.1)
Heart Failure Medication at baseline n (%)
Loop diuretic 2421 (72.9)
Thiazide diuretic 776 (23.4)
Loop or Thiazide 2879 (86.7)
Beta-Blocker 2542 (76.6)
ACE inhibitor 2696 (81.2)
AT1-receptor blocker 428 (12.9)
ACE inhibitor or AT1-receptor blocker 3063 (92.3)
Aldosterone antagonist 1284 (38.7)
Digitalis 1072 (32.3)
Anti-platelet or Anti-coagulant 3020 (91.0)
Blood pressure (mmHg)
Systolic 130.5 ± 16.1
Diastolic 77.0 ± 8.6
Heart rate (beats/min) 71.2 ± 10.9
BMI (kg/m2) 27.5 ± 4.4
Serum creatinine (umol/L) 112.8 ± 26.5
eGFR (ml/min/1.73 m/m2BSA) 58.5 ± 14.0
Table 1 Baseline characteristics of subjects in genetic
sub-study of CORONA (Continued)
hs-CRP (mg/L) 3.3 (0.02-230)
NT-proBNP (pmol/L) 151 (1–3868)
Lipids
Total cholesterol (mmol/L) 5.41 ± 1.07
LDL-cholesterol (mmol/L) 3.60 ± 0.94
HDL-cholesterol (mmol/L) 1.19 (0.47-3.55)
Apo-A1 (g/L) 1.51 ± 0.27
Apo-B (g/L) 1.28 ± 0.30
Apo-B/Apo-A (mean) 0.87 ± 0.24
Triglycerides (mmol/L) 1.68 (0.41-14.43)
Abbreviations: NYHA New York Heart Association, CABG Coronary Artery Bypass
Graft, PCI Percutaneous Coronary Intervention, ACE Acetylcholinesterase, AT1
Angiotensin-1, BMI body mass index, eGFR estimated Glomerular Filtration Rate,
hs-CRP high sensitive C-reactive protein, NT-proBNP N-terminal pro B-type natriuretic
peptide, LDL low-density lipoprotein, HDL high-density lipoprotein,
Apo apolipoprotein. Variables are expressed as mean (SD) when normally
distributed and as median (min-max) when non-normally distributed.
Haver et al. BMC Medical Genetics  (2014) 15:140 Page 3 of 8model with only genotype as predictor and if significant,
the following covariates were added to the adjusted model:
age, sex, ejection fraction, NYHA class, systolic blood pres-
sure, heart rate, body mass index, history of myocardial in-
farction, angina pectoris, diabetes mellitus, hypertension,
stroke, intermittent claudication, aortic aneurysm, percu-
taneous coronary intervention, coronary artery bypass graft
surgery, atrial fibrillation, implanted pacemaker, implanted
cardiac defibrillator, smoking status, serum creatinine, ala-
nine aminotransferase, creatine kinase, thyroid-stimulating
hormone, triglycerides, hsCRP and NT-proBNP, as ex-
plained in detail by Wedel et al. [10]. HF outcome determi-
nants were analysed using Cox regression of outcome
versus number of minor alleles. Analyses were conducted
unadjusted and after adjusted for the above mentioned co-
variates. We considered a P-value <0.0071 for the primary
endpoint statistically significant (Bonferroni adjustment
of <0.05 for 7 independent loci) and as suggestive for all
secondary endpoint analyses.
Results
The baseline characteristics of the study population are
presented in Table 1. The study population consisted of
3,320 HF patients with mean LVEF of 31% and a median
NT-proBNP level of 151 pmol/L. There was a high preva-
lence of hypertension, diabetes mellitus, and chronic kid-
ney disease in our population. Subjects were well treated
for HF, with 87% using diuretics, 77% using beta-blockers,
92% using ACE inhibitors or AT1-receptor antagonist,
and 91% were treated with an antiplatelet agent or anti-
coagulant. The mean follow-up time was 2.73 years, accu-
mulating 9,062 patient-years of follow-up. At baseline,
1,986 patients (60%) had a history of MI, and 823 (25%) a
history of CABG or PCI. Genotyping was successful in
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genotypes were consistent with the Hardy-Weinberg equi-
librium as calculated using the chi-square test for devi-
ation. Minor allele frequencies were similar in the current
analyses compared to the discovery GWAS [5,7]. Details
on genotyping can be found in Additional file 2: Table S1.
CAD loci and HF disease severity; LVEF and NT-proBNP
LVEF and NT-proBNP were taken as indicators of HF
disease severity and their association with the 7 genetic
loci was determined. Although some of the unadjusted
association P-values were smaller than 0.05 (Table 2,
Additional file 3: Table S2, and Additional file 4: Table S3),
we considered none of these loci associated with LVEF or
NT-proBNP considering the multiple testing burden of
these secondary endpoints.
Prognostic value of CAD loci for cardiovascular events
and disease progression in HF
Next, we tested the association between the CAD-associated
loci with HF disease outcome. None of the 7 loci predicted
the occurrence of the primary endpoint (composite end-
point of cardiovascular mortality, non-fatal myocardial in-
farction or non-fatal stroke, analysed as time to first event)
or death caused by cardiovascular events. When the individ-
ual components of the primary endpoint were considered,
we observed that the 1p13.3 (rs599839) locus, showed a bor-
derline association with all-cause mortality (HR 0.86, 95% CI
[0.74-1.00], P= 0.499) which became somewhat stronger
after adjustment for covariates (HR 0.74, [0.61-0.90],
P = 0.0025). Using ordered Jonckheere-Terpstra test, theTable 2 CAD loci (P < 0.05) and heart failure disease markers
Locus SNP Model n Beta est
LVEF 9p21.3 rs1333049 Unadj. 3,300 0.004
Adj.a 2,212 0.003
10q11.21 rs501120 Unadj. 3,300 0.005
Adj.a 2,216 0.002
15q22.33 rs17228212 Unadj. 3,303 −0.00
Adj.a 2,218 −0.00
log NT-proBNP (pmol/L) 10q11.21 rs501120 Unadj. 2,412 −0.1
Adj.a 2,216 −0.06
BMI (kg/m2) 1q41 rs17465637 Unadj. 3,298 0.35
Adj.a 2,220 0.3
Serum creatinine (umol/L) 10q11.21 rs501120 Unadj. 3,300 −2.0
Adj.a 2,216 −0.4
Abbreviations: SNP single nucleotide polymorphism, LVEF left ventricular ejection f
natriuretic peptide. aAdjusted analyses were adjusted for age, sex, ejection fractio
myocardial infarction, angina pectoris, diabetes mellitus, hypertension, stroke, int
coronary artery bypass graft surgery, atrial fibrillation, implanted pacemaker, implan
creatine kinase, thyroid-stimulating hormone, triglycerides, hsCRP and NT-proBNP [10]. A
variable, covariates were excluded from analyses (see Additional file 3: Table S2). Results1p13.3 locus also showed association with the total
number of hospitalizations due to cardiovascular causes
(P = 0.0093) and the 10q11.21 locus showed an associ-
ation with the number of hospitalizations due to wors-
ening HF. All associations with P < 0.05 are presented
in Table 3 (all associations are presented in Additional
file 5: Table S4 and Additional file 6: Table S5.Associations of CAD loci with lipid profile in HF
The 7 loci were evaluated for association with the avail-
able serum lipid profile parameters. After adjustments,
the 1p13.3 locus (rs599839) was associated with total choles-
terol (P= 1.1 × 10−4), low-density-lipoprotein (LDL) choles-
terol (P= 3.5 × 10−7), serum Apolipoprotein-B (Apo-B) levels
(P= 5.1 × 10−8) and the Apo-B/Apo-A1 ratio (P= 8.0 × 10−9).
Associations with lipid parameters with P-values smaller
than 0.05 are presented in Table 4 (all associations are pre-
sented in Additional file 7: Table S6.Discussion
HF is a common condition in which cardiac function is
affected, leading to a variety of symptoms like dyspnoea,
fatigue, and fluid retention. The most frequent cause of
HF is CAD. In the past few years, several genetic vari-
ants have been associated with CAD resulting in
new insight in the pathophysiology of CAD [5]. We
tested the hypothesis that the presence of variants asso-
ciated with prevalent CAD is also linked to increased se-
verity of HF and worse prognosis. Our findings lend
little support to this hypothesis. This was a candidatein genetic sub-study of CORONA
imate 95% CI P value Excluded from adjusted analysis
4 0.0015 - 0.0074 3.6 × 10−3 LVEF
8 0.0005 - 0.0071 2.3 × 10−2
4 0.0012 - 0.0097 1.2 × 10−2
2 −0.0025 - 0.0068 0.36
5 −0.0084 - -0.0016 4.0 × 10−3
31 −0.0069 - 0.0008 0.12
1 −0.20 - -0.01 2.7 × 10−2 log NT-proBNP (pmol/L)
4 −0.14 - 0.02 0.12
0.11 - 0.60 4.8 × 10−3 BMI (kg/m2)
0.03 - 0.58 2.9 × 10−2
1 −3.80 - -0.21 2.8 × 10−2 Serum creatinine (umol/L)
3 −2.25 - 1.39 0.65
raction, BMI body mass index, NT-proBNP N-terminal pro B-type
n, NYHA class, systolic blood pressure, heart rate, body mass index, history of
ermittent claudication, aortic aneurysm, percutaneous coronary intervention,
ted cardiac defibrillator, smoking status, serum creatinine, alanine aminotransferase,
s some covariates were also baseline variables or strongly associated to a baseline
of all regression analyses for all SNPs are in Additional file 4: Table S3.
Table 3 CAD loci (P < 0.05) and prognosis of ischemic heart failure in genetic sub-study of CORONA
Locus SNP Model n (total) n (events) Hazard ratio 95% CI P value
All-cause Mortality 1p13.3 rs599839 Unadj. 3,300 527 0.86* 0.74-1.00 4.99 × 10−2
Adj.a 2,218 341 0.74* 0.61-0.90 2.5 × 10−3
Mortality or WHF hospitalization 10q11.21 rs501120 Unadj. 3,300 1046 0.85* 0.75-0.97 1.2 × 10−2
Adj.a 2,216 670 0.82* 0.70-0.96 1.5 × 10−2
Number of hospitalizations due
to cardiovascular cause
1p13.3 rs599839 Ordered Jonkeheere-Terpstra test 9.3 × 10−3
Number of hospitalizations due
to WHF
10q11.21 rs501120 Ordered Jonkeheere-Terpstra test 3.2x10−2
Abbreviations: SNP single nucleotide polymorphism, WHF worsening heart failure. aAdjusted analyses were adjusted for age, sex, ejection fraction, NYHA class,
systolic blood pressure, heart rate, body mass index, history of myocardial infarction, angina pectoris, diabetes mellitus, hypertension, stroke, intermittent
claudication, aortic aneurysm, percutaneous coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, implanted pacemaker, implanted cardiac
defibrillator, smoking status, serum creatinine, alanine aminotransferase, creatine kinase, thyroid-stimulating hormone, triglycerides, hsCRP and NT-proBNP [10].
*directions were concordant with previous observations. [7] Regression data of all SNPs are presented in Additional file 5: Table S4.
Haver et al. BMC Medical Genetics  (2014) 15:140 Page 5 of 8variant analyses and some of the observed associations
are suggestive and require further replication.
The loci we evaluated included the 9p21 locus, which
is considered the most robust common genetic risk fac-
tor for CAD with the rs1333049 variant showing the
strongest signal for association with CAD in WTCCC
and German studies [5]. This locus harbours a large
non-coding transcript of unknown function, designated
the name CDKN2B antisense RNA (CDKN2BAS or
ANRIL). This locus is related to atherosclerotic diseaseTable 4 CAD loci (P < 0.05) and lipid characteristics in genetic
Locus SNP Model
Total cholestorol (mmol/L) 1p13.3 rs599839 Unadj.
Adj.a
10q11.21 rs501120 Unadj.
Adj.a
LDL cholesterol (mmol/L) 1p13.3 rs599839 Unadj.
Adj.a
10q11.21 rs501120 Unadj.
Adj.a
Triglycerides (mmol/L) 1p13.3 rs599839 Unadj.
Adj.a
9p21.3 rs1333049 Unadj.
Adj.a
Apo-B (g/L) 1p13.3 rs599839 Unadj.
Adj.a
10q11.21 rs501120 Unadj.
Adj.a
Apo-B/Apo-A1 ratio 1p13.3 rs599839 Unadj.
Adj.a
Abbreviations: SNP single nucleotide polymorphism, LDL low-density-lipoprotein, HDL h
aAdjusted analyses were adjusted for age, sex, ejection fraction, NYHA class, systolic blo
angina pectoris, diabetes mellitus, hypertension, stroke, intermittent claudication, aorti
surgery, atrial fibrillation, implanted pacemaker, implanted cardiac defibrillator, smokin
stimulating hormone, triglycerides, hsCRP and NT-proBNP [10]. As some covariates wer
were excluded from analysis (see Additional file 3: Table S2). Data for all SNPs are preseburden in different vascular beds [11] and deletion of
ANRIL in human aortic smooth muscle cells leads to a in-
crease in proliferative capacity in culture [12]. Further-
more, the rate of proliferation of vascular smooth muscle
cells is attenuated by the 9p21 genotype and the CAD risk
allele (C allele) increases vascular smooth muscle cell pro-
liferation, thereby likely playing an important role in the
development of atherosclerosis [13]. Despite these find-
ings, the presence of this genetic variant, and presumably
increased atherosclerotic burden, did not translate intosub-study of CORONA
n Beta estimate 95% CI P value
3,285 −0.14 −0.20 - -0.08 1.2 × 10−5
2,219 −0.14 −0.21 - -0.07 1.1 × 10−4
3,285 −0.07 −0.15 - -0.001 4.7 × 10−2
2,217 −0.05 −0.13 - 0.03 0.24
3,285 −0.16 −0.22 - -0.11 1.8 × 10−9
2,219 −0.17 −0.23 - -0.1 3.5 × 10−7
3,285 −0.07 −0.13 - -0.004 3.6 × 10−2
2,217 −0.05 −0.12 - 0.02 0.19
3,285 0.08 0.007 - 0.15 3.2 × 10−2
2,219 0.07 −0.005 - 0.15 6.6 × 10−2
3,285 −0.08 −0.14 - -0.02 7.0 × 10−3
2,213 −0.06 −0.13 - 0.001 5.4 × 10−2
3,264 −0.06 −0.07 - -0.04 2.2 × 10−10
2,218 −0.06 −0.08 - -0.04 5.1 × 10−8
3,267 −0.02 −0.04 - -0.002 2.8 × 10−2
2,216 −0.02 −0.05 - 0.002 7.5 × 10−2
3,264 −0.05 −0.06 - -0.03 3.3 × 10−11
2,218 −0.05 −0.07 - -0.03 8.0 × 10−9
igh-density-lipoprotein, Apo-B apolipoprotein-B, Apo-A1 apolipoprotein-A1.
od pressure, heart rate, body mass index, history of myocardial infarction,
c aneurysm, percutaneous coronary intervention, coronary artery bypass graft
g status, serum creatinine, alanine aminotransferase, creatine kinase, thyroid-
e also baseline variables or strongly associated to a baseline variable, covariates
nted in Additional file 7: Table S6.
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ischemic HF in the present study. A possible explanation
is that the effect of this locus acting through increased ath-
erosclerotic disease burden is confounded by events de-
fined by the severity of heart failure. In addition, the
vulnerability to develop HF given a similar atherosclerotic
disease burden might also differ among patients and could
be a consequence of complex gene-environment interac-
tions. The presence or absence of concomitant conditions
and diseases including diabetes, renal dysfunction, or
pulmonary disease may also modify the phenotype. Fur-
thermore, patients in our study were well treated with
beta-blockers, angiotensin-converting-enzyme inhibitors,
and aldosterone antagonists, which might further have de-
creased the differences between patients due to genetic
risk factors. Also related to optimisation of pharmacother-
apy, Wedel et al. calculated specifically for the CORONA
trial, that the proportionate contribution of myocardial in-
farction to total mortality, related to the atherosclerotic
disease burden, was relatively small. The Wald statistic of
myocardial infarction for total mortality was 3.9, while for
example log NT-proBNP showed a Wald statistic for total
mortality of 167 [10]. This suggests that the pathological
role of genetic risk variants acting through CAD might
also be relatively small, and could therefore have remained
undetected in our study. Nevertheless, the current sample
size of systematically collected ischemic HF patients with
DNA available to perform genotyping studies is the largest
available in the world to date and it will be difficult, if not
impossible, to extend the sample size within reasonable
timeframes. The results of this study concurs with the lack
of effect on CAD with rosuvastatin [10].
Considering prior knowledge, we also studied the associ-
ation of the genotyped genetic variants with lipid parame-
ters [14-16]. We were able to confirm previous reported
associations between the 1p13.3 locus (rs599839) and
lipids. We also provided novel data on this locus and its
association with apolipoproteins. The 1p13.3 locus was
most strongly associated with Apo-B levels (stronger than
the known LDL association), suggesting Apo-B is a candi-
date effector molecule. The genomic region at 1p13.3
encodes 4 genes: proline/serine-rich coiled protein 1
(PSRC1), cadherin EGF LAG sevenpass G-type receptor 2
(CELSR2), myosin-binding protein H-like (MYBHL), and
sortilin 1 (SORT1). Recent studies have revealed a role
for SORT1 in Apo-B secretion and LDL catabolism: over-
expression of SORT1 resulted in increased serum LDL
and loss-of-function mutations were associated with pro-
tection against hypercholesterolemia and atherosclerosis
[17,18]. In our secondary analyses we observed an associ-
ation with all-cause mortality and the number of hospitali-
zations due to cardiovascular causes for the 1p13.3 locus.
As these were secondary analyses, which would not survive
strict adjustment for multiple testing, the interpretation ofthese findings should be cautious as they require further
confirmation. In addition, the explanation and possible rela-
tion to lower cholesterol and apolipoprotein levels cannot
be deducted from the current study.
Among the strengths of the present study are the size
and quality of the study cohort, which is the largest
heart failure cohorts with DNA available to date. Patient
characteristics and outcomes have been collected and
documented systematically within the framework of a
clinical trial. However, there are some limitations which
we need to address. At first, we have limited the variants
tested to the N.J. Samani paper published in 2007 [5]
and the variants reported by the Coronary Artery Disease
Consortium in 2009 [7]. Recent GWA studies have identi-
fied additional variants involved in CAD development.
The recent publication by the CARDIoGRAMplusC4D
consortium reported 46 genetic variants associated with
CAD risk [19]. We cannot exclude that there might be
variants among these 46 that are related to heart failure
outcomes and this remains an objective for further study.
We performed a post-hoc power calculation to consider
the possibility that our study might have lacked power
[20]. Assuming an effect size of the risk variant comparable
to the CAD discovery GWAS (genotype relative risk Aa =
1.3; genotype relative risk AA= 1.6) [5,7], we calculated the
power to detect a significant effect for a variant (prevalence
cases = 0.175; number of cases = 581; control:case ratio =
4.7). The power of our analyses ranged from 0.90 to 0.91
depending on the frequency of the risk allele (ranging from
0.25 to 0.55). Future studies with larger sample sizes, con-
taining all CAD loci, are warranted to further evaluate the
influence of CAD genetic loci in heart failure.
Conclusions
Genetic variants associated with CAD and atherosclerotic
disease burden are not associated with the severity and
prognosis of patients with ischemic HF in the CORONA
trial. The observed secondary association of the 1p13.3
locus with all-cause mortality requires confirmation in fur-
ther studies.Additional files
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